France's Abivax Looks A Likely M&A Target
ABX464 Could Be IBD Gamechanger
With a candidate for ulcerative colitis set to go into Phase III soon with a safety profile that looks cleaner than anti-TNFs and the JAK class, the French biotech could soon be getting some interesting offers.
